PredicineATLAS™ is the largest liquid biopsy assay for a complete cancer mutational landscape and accurate tumor mutation burden (TMB) calculation.
Cancer immunotherapies have the potential to harness the immune system to treat cancer. However, not all cancer patients respond to cancer immunotherapies. TMB and MSI are emerging quantitative clinical biomarkers that can help predict response to certain cancer immunotherapies. TMB-high and MSI-high patients have shown improved response rate to immunotherapies.
PredicineATLAS™ is a laboratory developed test. It is for research use only.
Our pilot program is available to select biopharma and academic partners to accelerate biomarker discoveries and biomarker-driven clinical studies. To initiate a study, contact us via the form below.